Keku Temitope O, Lund Pauline Kay, Galanko Joseph, Simmons James G, Woosley John T, Sandler Robert S
Department of Medicine, University of North Carolina, Chapel Hill, 27599-7555, USA.
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2076-81. doi: 10.1158/1055-9965.EPI-05-0239.
Compelling evidence from epidemiologic studies indicates that elevated circulating insulin-like growth factor (IGF)-I, insulin resistance, and associated complications, such as elevated fasting plasma insulin, glucose and free fatty acids, glucose intolerance, increased body mass index, and visceral adiposity, are linked with increased risk of colorectal cancer. However, the role of insulin and markers of glucose control in the development of adenomas, precursors to colorectal cancer, has not been fully explored. We evaluated the relationship between plasma insulin, glucose, IGF-I, IGF-II, IGF-binding protein-3 (IGFBP-3), apoptosis, and colorectal adenomas in a case-control study. Participants were drawn from consenting patients undergoing colonoscopy at the University of North Carolina hospitals (Chapel Hill, NC). Participants were classified as cases or controls based on whether they had one or more colorectal adenomatous polyps. Fasting plasma insulin, IGF-I, IGF-II, and IGFBP-3 levels were assessed by ELISA. Glucose was measured by glucose hexokinase assay. Apoptosis was assessed by morphology on H&E-stained sections. Dietary and lifestyle information were obtained by telephone interview. Logistic regression was used to examine the association between adenoma status and insulin-IGF markers. Adenoma cases (n = 239) and adenoma-free controls (n = 517) provided rectal biopsies and/or blood samples and interview data. Consistent with prior findings, cases were more likely to be males, older, have higher waist-to-hip ratio, lower calcium intake, lower apoptosis, and less likely to report nonsteroidal anti-inflammatory drug use. Those in the highest quartile of insulin (adjusted odds ratio, 2.2; 95% confidence interval, 1.1-4.2) and glucose (adjusted odds ratio, 1.8; 95% confidence interval, 0.9-3.6) were more likely to have an adenoma compared with the lowest quartile. Similarly, subjects in the highest two quartiles of insulin were more likely to be in the lowest two quartiles of apoptosis. Overall, there were no significant differences between mean circulating levels of glucose, IGF-I, IGF-II, and IGFBP-3 among cases and controls and no association between these variables and apoptosis. The results provide novel evidence that elevated insulin and glucose are associated with increased adenoma risk and decreased apoptosis in normal rectal mucosa. These findings suggest that insulin may act early in the adenoma-carcinoma sequence to promote the development of colorectal adenoma by decreasing apoptosis in the normal mucosa.
流行病学研究的有力证据表明,循环中胰岛素样生长因子(IGF)-I升高、胰岛素抵抗以及相关并发症,如空腹血浆胰岛素、血糖和游离脂肪酸升高、葡萄糖耐量异常、体重指数增加和内脏肥胖,都与结直肠癌风险增加有关。然而,胰岛素及血糖控制指标在结直肠癌前体腺瘤发生发展中的作用尚未得到充分研究。我们在一项病例对照研究中评估了血浆胰岛素、血糖、IGF-I、IGF-II、IGF结合蛋白-3(IGFBP-3)、细胞凋亡与结直肠腺瘤之间的关系。研究对象来自北卡罗来纳大学医院(北卡罗来纳州教堂山)同意接受结肠镜检查的患者。根据是否有一个或多个结直肠腺瘤性息肉,将参与者分为病例组或对照组。采用酶联免疫吸附测定法评估空腹血浆胰岛素、IGF-I、IGF-II和IGFBP-3水平。通过葡萄糖己糖激酶法测定血糖。通过苏木精-伊红染色切片的形态学评估细胞凋亡情况。通过电话访谈获取饮食和生活方式信息。采用逻辑回归分析腺瘤状态与胰岛素-IGF标志物之间的关联。腺瘤病例(n = 239)和无腺瘤对照组(n = 517)提供了直肠活检组织和/或血液样本以及访谈数据。与先前的研究结果一致,病例组更可能为男性、年龄较大、腰臀比更高、钙摄入量更低、细胞凋亡率更低,且报告使用非甾体抗炎药的可能性更小。胰岛素和血糖处于最高四分位数的人群与最低四分位数的人群相比,患腺瘤的可能性更高(校正比值比,2.2;95%置信区间,1.1 - 4.2)以及(校正比值比,1.8;95%置信区间,0.9 - 3.6)。同样,胰岛素处于最高两个四分位数的受试者更可能处于细胞凋亡最低的两个四分位数。总体而言,病例组和对照组之间葡萄糖、IGF-I、IGF-II和IGFBP-3的平均循环水平无显著差异,且这些变量与细胞凋亡之间无关联。研究结果提供了新的证据,表明胰岛素和血糖升高与腺瘤风险增加以及正常直肠黏膜细胞凋亡减少有关。这些发现表明,胰岛素可能在腺瘤 - 癌序列的早期起作用,通过减少正常黏膜中的细胞凋亡来促进结直肠腺瘤的发展。